- Home
- WERN vs BCRX Comparison
WERN vs BCRX Comparison
Compare WERN & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WERN
- BCRX
- Stock Information
- Founded
- WERN 1956
- BCRX 1986
- Country
- WERN United States
- BCRX United States
- Employees
- WERN N/A
- BCRX N/A
- Industry
- WERN Trucking Freight/Courier Services
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WERN Industrials
- BCRX Health Care
- Exchange
- WERN Nasdaq
- BCRX Nasdaq
- Market Cap
- WERN 1.7B
- BCRX 1.9B
- IPO Year
- WERN N/A
- BCRX 1994
- Fundamental
- Price
- WERN $28.72
- BCRX $8.96
- Analyst Decision
- WERN Hold
- BCRX Strong Buy
- Analyst Count
- WERN 14
- BCRX 10
- Target Price
- WERN $31.00
- BCRX $16.70
- AVG Volume (30 Days)
- WERN 851.5K
- BCRX 3.3M
- Earning Date
- WERN 07-29-2025
- BCRX 08-04-2025
- Dividend Yield
- WERN 1.91%
- BCRX N/A
- EPS Growth
- WERN N/A
- BCRX N/A
- EPS
- WERN 0.29
- BCRX N/A
- Revenue
- WERN $2,973,292,000.00
- BCRX $503,485,000.00
- Revenue This Year
- WERN $0.29
- BCRX $39.04
- Revenue Next Year
- WERN $5.89
- BCRX $13.26
- P/E Ratio
- WERN $102.26
- BCRX N/A
- Revenue Growth
- WERN N/A
- BCRX 41.67
- 52 Week Low
- WERN $23.02
- BCRX $6.02
- 52 Week High
- WERN $42.48
- BCRX $11.31
- Technical
- Relative Strength Index (RSI)
- WERN 54.04
- BCRX 38.09
- Support Level
- WERN $28.22
- BCRX $8.69
- Resistance Level
- WERN $30.50
- BCRX $9.23
- Average True Range (ATR)
- WERN 0.89
- BCRX 0.31
- MACD
- WERN 0.10
- BCRX -0.06
- Stochastic Oscillator
- WERN 53.52
- BCRX 19.57
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.